Ocugen, Inc. (OCGN)

$ 6.34
-0.35 (-5.23%)
-
Symbol OCGN
Price $ 6.34
Beta 2.594
Volume Avg. 64.72M
Market Cap 1.26B
Shares () -
52 Week Range 0.185-18.77
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -102.82% Strong Sell
ROA -46.34% Strong Sell
Operating Margin -
Debt / Equity 15.83% Neutral
P/E -
P/B 25.41 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

How to Buy Biotech Stocks This Summer

How to Buy Biotech Stocks This Summer

It pays to know what could cause them to move and when. ...

The Motley Fool
Where Will Ocugen Be in 1 Year?

Where Will Ocugen Be in 1 Year?

This biotech underdog's dream of selling a coronavirus vaccine in the U.S. just went up in smoke. ...

The Motley Fool
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm

OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockhol...

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ocugen, Inc. (NASDAQ: OCGN) on behalf of Ocugen stockholders. Our investigation concerns ... ...

Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc...

LOS ANGELES--(BUSINESS WIRE)---- $OCGN #OCGN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. ...

Business Wire
Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks

Ocugen (OCGN) to File Coronavirus Vaccine BLA in US, Stock Tanks

Ocugen (OCGN) to submit a BLA for its COVID-19 vaccine candidate, Covaxin, in the United States. The company will no longer pursue an EUA for the vaccine candidate. ...

Zacks Investment Research
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Ocugen, Inc.

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securi...

New York, New York--(Newsfile Corp. - June 11, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) concerning possible violations of federal securities laws. To... ...

Newsfile Corp
4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now

4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now

Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com. ...

PennyStocks
OCGN Stock Price: 28.14% Decrease Explanation

OCGN Stock Price: 28.14% Decrease Explanation

The stock price of Ocugen Inc (NASDAQ: OCGN) fell by 28.14% today. This is why it happened. ...

Pulse2
Why Ocugen Plummeted by Nearly 30% Today

Why Ocugen Plummeted by Nearly 30% Today

The company won't be getting emergency use authorization for Covaxin after all. ...

The Motley Fool
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. a...

LOS ANGELES--(BUSINESS WIRE)---- $OCGN #OCGN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. ...

Business Wire

About


Dr. Shankar Musunuri
Healthcare
Biotechnology
Nasdaq Global Select

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 49 full-time employees. The firm offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The firm is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The firm is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).